Dacomitinib resistance management

Dacomitinib (Dacomitinib) is a targeted therapy approved for the treatment of non-small cell lung cancer (NSCLC). However, long-term use of dacomitinib may lead to the development of drug resistance in patients. However, since each person's constitution is different, the drug resistance response is also different. If drug resistance occurs after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

Drug resistance is often the result of a combination of multiple factors. Doctors can adjust treatment strategies based on the patient's genotype and molecular characteristics to deliver treatment in an individualized manner. During dacomitinib treatment, resistance is sometimes reduced by stopping the drug for a period of time. Doing so restores the tumor's sensitivity to dacomitinib. When patients develop resistance to dacomitinib, switching to other targeted therapies can be considered. Doctors may choose an appropriate alternative medication based on a patient's specific condition. Another approach is to combine dacomitinib with other related anticancer drugs. This combination therapy can delay or reverse drug resistance by acting on different molecular targets simultaneously.

The original drug of dacomitinib has been launched in China and has entered the scope of Class B medical insurance. The price of the common specification 15mg*30 tablets per box may be more than 1,000 yuan; the European version of dacomitiniboriginal drug sold overseas, the specification 45mg*30 tablets may be more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).